Health Economics›Head and neck cancer›Adjuvant therapy

Adjuvant therapy

Head and neck cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy

No data points — cost or PFS missing for current selection.

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Docetaxel, Cetuximab, RT Variant #01	—	R 159 520	45d	—	—	—	—	—
Cisplatin, Cetuximab, RT Variant #01	—	R 157 937	45d	—	—	—	—	—
Cisplatin and RT Variant #01	—	R 1 500	49d	—	72.0 mo	—	—	3
Tegafur and uracil monotherapy Partial	—	—	—	—	—	—	—	—
Placebo Partial	—	—	—	~4.2 mo	~8.0 mo	—	—	145
Radiation therapy N/A - radiation Partial	—	—	49d	—	32.0 mo	—	—	1
UFT monotherapy Variant #04 Partial	—	—	28d	—	—	—	—	4
Tegafur and Uracil Partial	—	—	—	—	—	—	—	—

8 of 8 regimens shown